Avelumab Plus Axitinib for Previously Treated NSCLC or Treatment-Naïve Cisplatin-Ineligible Urothelial Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
ESMO Open
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A phase II open-label trial of avelumab plus axitinib in previously treated non-small-cell lung cancer or treatment-naïve, cisplatin-ineligible urothelial cancer
ESMO Open 2023 May 02;8(3)101173, G Galffy, I Lugowska, EV Poddubskaya, BC Cho, MJ Ahn, JY Han, WC Su, RJ Hauke, SH Dyar, DH Lee, P Serwatowski, DL Estelles, VR Holden, YJ Kim, V Vladimirov, Z Horvath, A Ghose, A Goldman, A di Pietro, J Wang, DA Murphy, A Alhadab, M LaskovFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.